Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative

Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis

Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin

Hematopoietic α7 nicotinic acetylcholine receptor deficiency increases inflammation and platelet activation status, but does not aggravate atherosclerosis

Salsalate activates brown adipose tissue in mice

Brown fat activation reduces hypercholesterolaemia and protects from atherosclerosis development

Anacetrapib reduces (V)LDL-cholesterol by inhibition of CETP activity and reduction of plasma PCSK9

Metformin lowers plasma triglycerides by promoting vldl-triglyceride clearance by brown adipose tissue in mice

Long-term niacin treatment induces insulin resistance and adrenergic responsiveness in adipocytes by adaptive downregulation of phosphodiesterase 3B

RP105 deficiency aggravates cardiac dysfunction after myocardial infarction in mice

Brown adipose tissue volume in healthy lean south Asian adults compared with white Caucasians: A prospective, case-controlled observational study

P430RP105 deficiency aggravates cardiac dysfunction after myocardial infarction in mice

Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration

Peripheral cannabinoid 1 receptor blockade activates brown adipose tissue and diminishes dyslipidemia and obesity

Sympathetic nervous system control of triglyceride metabolism: Novel concepts derived from recent studies

Inhibition of the central melanocortin system decreases brown adipose tissue activity

Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice

Apolipoprotein A5 deficiency aggravates high-fat diet-induced obesity due to impaired central regulation of food intake

Acute Central Neuropeptide Y Administration Increases Food Intake but Does Not Affect Hepatic Very Low-Density Lipoprotein (Vldl) Production in Mice

CD36 is important for adipocyte recruitment and affects lipolysis